Stop Treatment with Bulevertide in patients with compensated liver disease and chronic HDV infection clinical trials

Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of HDV Infection

This study looks for ways to tell which patients with Hepatitis D can safely stop a treatment called Bulevirtide without their infection coming back. We want to find signs (biomarkers) that show who can stop treatment and stay well.